Quarterly Result30 Jan 2026, 12:56 pm
Strides Pharma Science Ltd Reports Highest Ever Quarterly EBITDA of Rs.2,359 million in Q3 FY26
AI Summary
Strides Pharma Science Ltd, a global pharmaceutical company, announced its consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a revenue of Rs.11,946 million, a growth of 3.6% YoY. The gross margin improved to 61.2%, up 280bps YoY. The EBITDA grew 12.2% YoY to Rs.2,359 million, with an EBITDA margin of 19.8%. The operational PAT grew 38.6% YoY to Rs.1,282 million. The company's strong focus on profitability resulted in gross margin expansion and EBITDA margin increase. The company's ongoing commitment to ESG continues to be recognized with an improved S&P Global Corporate Sustainability Assessment score.
Key Highlights
- Revenue at Rs.11,946 million, grew 3.6% YoY
- Gross margin improved to 61.2%, up 280bps YoY
- EBITDA grew 12.2% YoY to Rs.2,359 million
- Operational PAT at Rs.1,282 million, grew 38.6% YoY
- Improved S&P Global Corporate Sustainability Assessment score of 80, marking a 5 point increase over the previous year